Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration.
OBJECTIVE
The ability of the bone marrow cells to differentiate into liver, pancreas, and other tissues led to the speculation that these cells might be the source of adult stem cells found in these organs. The present study analyzed whether the bone marrow cells are a source of hepatic oval cells involved in rat liver regeneration induced by 2-acetylaminofluorene (2-AAF) and 70% partial hepatectomy (PHx).


METHODS
Three groups of mutant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were required for the study. Groups A and B received the mitotic inhibitor monocrotaline, followed by male F344 (DPPIV(+)) bone marrow transplantation. Next, group A received PHx only, while group B received the 2-AAF/PHx required for the oval cell activation. The last group C was used to analyze the effects of monocrotaline on transplanted bone marrow cells. These rats underwent transplantation with bone marrow cells and were then treated with monocrotaline. Subsequently, the animals were treated with 2-AAF/PHx.


RESULTS
In group A, DPPIV(+) hepatocytes were found in the liver. Group B showed that approximately 20% of the oval cell population expressed both donor marker (DPPIV) and alpha-fetoprotein, and some differentiated into hepatocytes. In contrast, animals in group C failed to significantly induce oval cells with the donor DPPIV antigen. In addition, X/Y-chromosome analysis revealed that fusion was not contributing to differentiation of donor-derived oval cells.


CONCLUSIONS
Our results suggest that under certain physiologic conditions, a portion of hepatic stem cells might arise from the bone marrow and can differentiate into hepatocytes.
Oh
Seh-Hoon
SH
Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
Witek
Rafal P
RP
Bae
Si-Hyun
SH
Zheng
Donghang
D
Jung
Youngmi
Y
Piscaglia
Anna C
AC
Petersen
Bryon E
BE
D015073:2-Acetylaminofluorene; D000818:Animals; D030801:Animals, Genetically Modified; D050256:Antimitotic Agents / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods; D002454:Cell Differentiation; D049109:Cell Proliferation; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury; D018819:Dipeptidyl Peptidase 4 / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D006498:Hepatectomy; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000637:transplantation; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D008107:Liver Diseases / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D008115:Liver Regeneration; D008297:Male; D016686:Monocrotaline / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344 / Q000235:genetics; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D014960:X Chromosome / Q000378:metabolism; D014998:Y Chromosome / Q000378:metabolism; D000509:alpha-Fetoproteins / Q000378:metabolism
D050256:Antimitotic Agents; D000509:alpha-Fetoproteins; D016686:Monocrotaline; D015073:2-Acetylaminofluorene; D018819:Dipeptidyl Peptidase 4